For the Inventor, By the Inventor

Enter inventor name

Guangdong, China

Baiyong Li

USPTO Granted Patents = 17 (Patent Applications = 13)

CIPO Patents = 2 (Patent Applications = 22)

EPO Patents = 7 (Patent Applications = 41)

Average Co-Inventor Count = 5.3

ph-index = 2

Forward Citations = 5(Granted Patents)

Location History:

Zhongshan, CN (2019 - 2024)
Guangdong, CN (2019 - 2024)

Company Filing History:

Akeso Biopharma, Inc.

Ad Pharmaceutical Co., Inc.

Sichuan Kelun-biotech Biopharmaceutical Co., Ltd.

Taizhou Hanzhong Biopharmaceutics, Inc.

Akeso Pharmaceuticals, Inc.

Zeda Biopharmaceuticals, Inc.

Cttq-akeso (shanghai) Biomed. Tech. Co., Ltd.

8. 1 out of 118

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

where one patent can have more than one assignee

Years Active: 2019-2025

where 'Filed Patents' based on already Granted Patents

17 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12447208 - Anti-CTLA4 monoclonal antibody or its antigen binding fragments, pharmaceutical compositions and uses (2025-10-21),

2. 12390458 - Therapeutic combination of quinoline derivative and antibody (2025-08-19),

3. 12286473 - Anti-IL-1β antibody and pharmaceutical composition thereof and use of same (2025-04-29),

4. 12195527 - Anti-PD-1/VEGFA bifunctional antibody, pharmaceutical composition thereof (2025-01-14),

5. 12076398 - Anti-PD1 monoclonal antibody, pharmaceutical composition thereof and use thereof (2024-09-03),

6. 11976115 - Antibody binding to human IL-1β, preparation method therefor and use thereof (2024-05-07),

7. 11680095 - Monoclonal antibody against nerve growth factor, and encoding gene and use thereof (2023-06-20),

8. 11578128 - Anti-CTLA4 and anti-PD-1 bifunctional antibody, pharmaceutical composition thereof and use thereof (2023-02-14),

9. 11479608 - Anti-CTLA4 antibodies (2022-10-25),

10. 11402383 - Nucleic acid encoding PCSK9 antibody (2022-08-02),

11. 11291720 - Anti-CTLA4 monoclonal antibody or its antigen binding fragments, pharmaceutical compositions and uses (2022-04-05),

12. 11136413 - PDL-1 antibody, pharmaceutical composition thereof, and uses thereof (2021-10-05),

13. 11104734 - Anti-PD-1 monoclonal antibody (2021-08-31),

14. 10858433 - Monoclonal antibody against PD-1 and application thereof (2020-12-08),

15. 10670604 - PCSK9 antibody, and pharmaceutical composition and use thereof (2020-06-02),

Title: The Innovative Contributions of Baiyong Li

Introduction

Baiyong Li is a prominent inventor based in Guangdong, China. He has made significant contributions to the fields of tumor therapy and molecular immunology. With a total of 17 patents, his work has had a substantial impact on medical research and treatment options.

Latest Patents

One of his latest patents is the development of an anti-CTLA4 monoclonal antibody or its antigen binding fragments, along with pharmaceutical compositions and uses. This invention aims to block the binding of CTLA4 to B7, thereby relieving immunosuppression and activating T lymphocytes. Another notable patent involves a therapeutic combination of a quinoline derivative and an antibody, which includes an immune checkpoint inhibitor and a tyrosine kinase inhibitor. This combination has shown promising activity against lung and liver tumors.

Career Highlights

Baiyong Li has worked with several notable companies in the pharmaceutical industry, including Akeso Biopharma, Inc. and Ad Pharmaceutical Co., Inc. His expertise in immunology and tumor therapy has positioned him as a key figure in the development of innovative treatments.

Collaborations

Throughout his career, Baiyong Li has collaborated with esteemed colleagues such as Yu Xia and Zhongmin Maxwell Wang. These partnerships have further enhanced his research and contributions to the field.

Conclusion

Baiyong Li's innovative work in the realm of tumor therapy and molecular immunology continues to pave the way for advancements in medical treatments. His numerous patents reflect his dedication to improving healthcare outcomes.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com

Loading…